Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy-Reference-Cited by-同舟云学术

Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy

Published:2016-03 Issue:3 Volume:27 Page:545-546
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Tannock I.F.,Sternberg C.N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/3/545/6676670/mdv600.pdf

Reference5 articles.

1. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann Oncol,2015

2. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial;Gravis;Lancet Oncol,2013

3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

4. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476);James;J Clin Oncol,2015

5. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials;Templeton;Ann Oncol,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. pH-Sensitive Black Phosphorous–Incorporated Hydrogel as Novel Implant for Cancer Treatment;Journal of Pharmaceutical Sciences;2019-08

2. Management algorithms for metastatic prostate cancer;Canadian Urological Association Journal;2019-01-18

3. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis;European Journal of Cancer;2018-11

4. Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer;Targeted Oncology;2018-08-30

5. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer;BJU International;2018-06-13